Teladoc Health (NYSE:TDOC) Issues Earnings Results

Teladoc Health (NYSE:TDOC) released its earnings results on Wednesday. The health services provider reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.03, Zacks reports. Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. Teladoc Health updated its Q3 2026 guidance to -0.300–0.200 EPS and its FY 2026 guidance to -1.000–0.750 EPS.

Teladoc Health Stock Performance

Shares of NYSE:TDOC traded down $0.15 during trading hours on Wednesday, hitting $9.21. The stock had a trading volume of 6,707,673 shares, compared to its average volume of 5,386,222. The stock’s fifty day simple moving average is $8.16 and its 200 day simple moving average is $6.54. Teladoc Health has a 1-year low of $4.40 and a 1-year high of $9.89. The firm has a market capitalization of $1.66 billion, a price-to-earnings ratio of -9.50 and a beta of 2.10. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.72 and a current ratio of 2.80.

Insiders Place Their Bets

In other Teladoc Health news, insider Carlos Nueno sold 6,196 shares of Teladoc Health stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $47,275.48. Following the sale, the insider owned 57,671 shares of the company’s stock, valued at $440,029.73. The trade was a 9.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Adam C. Vandervoort sold 7,906 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $60,322.78. Following the transaction, the insider owned 110,261 shares of the company’s stock, valued at $841,291.43. This trade represents a 6.69% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 39,195 shares of company stock valued at $299,058. Corporate insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Teladoc Health

Hedge funds and other institutional investors have recently modified their holdings of the stock. IFP Advisors Inc grew its position in Teladoc Health by 412.1% in the 3rd quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after buying an additional 3,210 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Teladoc Health by 177.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock valued at $31,000 after acquiring an additional 2,810 shares during the period. Van ECK Associates Corp raised its holdings in Teladoc Health by 101.4% during the fourth quarter. Van ECK Associates Corp now owns 9,150 shares of the health services provider’s stock worth $64,000 after purchasing an additional 4,607 shares in the last quarter. Johnson Financial Group Inc. lifted its position in Teladoc Health by 41,045.8% in the third quarter. Johnson Financial Group Inc. now owns 9,875 shares of the health services provider’s stock worth $76,000 after purchasing an additional 9,851 shares during the period. Finally, Cibc World Markets Corp bought a new position in Teladoc Health during the 4th quarter valued at $82,000. 76.82% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently weighed in on TDOC. Canaccord Genuity Group raised their target price on shares of Teladoc Health from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Citigroup upped their target price on Teladoc Health from $6.00 to $7.00 and gave the company a “neutral” rating in a report on Tuesday, May 5th. Weiss Ratings upgraded Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Finally, Bank of America boosted their price objective on Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Five analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Teladoc Health presently has a consensus rating of “Hold” and an average target price of $7.57.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.